Acesso livre
Acesso livre

Infectologia

Com dados de dispositivos móveis (wearable data), um sistema de alerta em tempo real pode ser útil na detecção precoce de Covid-19 e outros eventos estressores.

1 Dez, 2021 | 15:41h

Real-time alerting system for COVID-19 and other stress events using wearable data – Nature Medicine

Comentário: Scientists develop a smartwatch-based device for early detection of COVID-19 – News Medical

 

Comentário no Twitter

 

Painel do FDA recomenda (por pouco) a autorização da primeira pílula antiviral para tratar COVID-19.

1 Dez, 2021 | 15:39h

FDA panel narrowly recommends authorization of first antiviral pill to treat COVID – STAT

Ver também: An FDA panel supports Merck COVID drug in mixed vote – NPR

Conteúdos relacionados:

[Press release – not published yet] Merck’s new Covid-19 pill Molnupiravir updated data shows reduced efficacy (30%) for preventing hospitalization and death compared to initial results (50%). Absolute risk reduction of hospitalization and death fell from 7% to 3%.

8 lingering questions about the new Covid pills from Merck and Pfizer.

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

Mortalidade total de pacientes de COVID na Alemanha que receberam ECMO durante as primeiras 3 ondas da pandemia.

1 Dez, 2021 | 15:37h

Complete countrywide mortality in COVID patients receiving ECMO in Germany throughout the first three waves of the pandemic – Critical Care

Outro estudo randomizado mostrou que o plasma convalescente não beneficia pacientes internados com Covid-19.

1 Dez, 2021 | 15:36h

Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial – JAMA Network Open

Conteúdos relacionados:

M-A: Convalescent plasma does not reduce mortality in COVID-19.

RCT: Another study shows convalescent plasma does not improve outcomes in critically ill patients with Covid-19.

RCT: Convalescent plasma does not improve outcomes and may be harmful to hospitalized patients with COVID-19.

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms.

M-A: Convalescent plasma is safe but does not improve outcomes in the treatment of COVID-19.

RECOVERY Trial: No benefit from convalescent plasma in patients admitted to hospital with COVID-19.

 

Comentário no Twitter

 

O fim da pandemia de COVID-19 está atrelado à confiança: a ciência sozinha não vai nos tirar disso.

1 Dez, 2021 | 15:34h

Ending the COVID-19 Pandemic Hinges on Trust – Think Global Health

 

Comentário no Twitter

 

Diretrizes desenvolvidas sob pressão. O caso das diretrizes “rápidas” e de baixa qualidade para COVID-19 e soluções potenciais.

1 Dez, 2021 | 15:33h

Guidelines developed under pressure. The case of the COVID-19 low-quality “rapid” guidelines and potential solutions – Journal of Clinical Epidemiology

Estudo de coorte | Condições alérgicas parecem estar relacionadas a menor risco de infecção por COVID-19.

1 Dez, 2021 | 15:32h

Comunicado de imprensa: Allergic conditions linked to lower COVID-19 infection risk – BMJ

Estudo original: Risk factors for developing COVID-19: a population-based longitudinal study (COVIDENCE UK) – Thorax

Estimativas globais da supressão viral em 31 países mostram que muitos portadores do vírus HIV falharam em atingir uma supressão viral durável.

1 Dez, 2021 | 15:25h

Comunicado de imprensa: Too many people with HIV fail to achieve durable viral suppression – NIH News Releases

Estudo original: Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries – The Lancet HIV (link para o resumo – $ para o texto completo)

Resumo Técnico e Ações Prioritárias da OMS | Aumentando a preparação para a variante Ômicron.

30 Nov, 2021 | 12:28h

Enhancing Readiness for Omicron (B.1.1.529): Technical Brief and Priority Actions for Member States – World Health Organization

Comentários:

The World Health Organization warns of very high risk posed by the omicron variant – NPR

Omicron Covid variant poses very high global risk, says WHO – The Guardian

Ver também os artigos mais recentes sobre o assunto:

Statement On Omicron Variant – Infectious Diseases Society of America

Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear – The BMJ

Helen Salisbury: Omicron—panic mongering or appropriate caution? – The BMJ

The Omicron variant underscores the global stakes of Covid-19 vaccine inequity – STAT

EXPLAINER: What we know and don’t know about omicron variant – Associated Press

Omicron: How do you detect it? – BBC

Are new COVID variants like Omicron linked to low vaccine coverage? Here’s what the science says – The Conversation

Omicron: why the WHO designated it a variant of concern – The Conversation

It looks like Omicron causes milder illness – is this how COVID becomes endemic? – The Conversation

As Omicron spreads, studies suggest that travel bans alone don’t do much good – NPR

Estudo randomizado | A transmissão do SARS-CoV-2 foi evitada por meio de uma intervenção de prevenção abrangente em um evento grande, ao vivo e em espaço aberto.

30 Nov, 2021 | 12:26h

Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial – The Lancet Infectious Diseases

Comentário convidado: Concerts and COVID: can the beat go on? – The Lancet Infectious Diseases

Conteúdo relacionado: No COVID-19 cases found after a well-controlled indoor concert.

 

Comentários no Twitter

 

Mantenha-se atualizado em sua especialidade

 

Escolha quantas especialidades quiser.